Cannabis stocks surged nearly 91% ahead of the Schedule 3 Executive Order but fell 29% in a “sell the news” correction, largely due to profit-taking and misconceptions about immediate rescheduling, ATB Capital tells investors in a research note. The pullback is viewed as an overreaction, creating a buying opportunity, with rescheduling potentially effective in 1H26 and substantial upside, the firm says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MSOS:
- Trump increasing medical marijuana and cannabidiol research
- President Trump says marijuana order ‘not legalization’
- AdvisorShares Pure US Cannabis ETF halted for volatility after falling 6%
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Canopy Growth Stock (CGC) Climbs on $91M Deal to Buy Out MTL Cannabis